Skandinaviska Enskilda Banken (SEB)
EIGR

Skandinaviska Enskilda Banken (SEB)’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,374
Closed -$762K – 924
2022
Q3 		$762K Hold
3,374
– – 0.01% 717
2022
Q2 		$638K Hold
3,374
– – ﹤0.01% 774
2022
Q1 		$840K Buy
+3,374
New +$533K ﹤0.01% 771

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s EIGR Position: Q4 2022 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 3,374 shares — an estimated $762K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in EIGR in Q1 2022 and held it in 3 quarters. The position peaked at $840K in Q1 2022. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 3,374 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $762K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2022 and held it in 3 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Eiger BioPharmaceuticals, Inc. position peaked at $840K in Q1 2022.
  • 81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2022, filed 8 Feb 2023.